To experimentally test whether germline CHEK2 variants promote evolution of ER+ cancer in the premenopausal breast, we used a genetically engineered mouse model expressing the CHEK2*1100delC variant (p. Thr410fs*15) (40), the most common variant in our study (Fig. 2E). Here, CHEK2 is linked to cancer.